Price action, page-7

Certainly looks to be "in play". And despite the recent rise the share price is still cheap relative to the potential value if the MIS416 trial brings home the goods. Recall that up to ?10 large drug companies are following this one very closely and that IIL intends to conduct a competitive bidding process if the trial is successful, meaning that the payoff could be significant -- especially if we end up with the hoped-for "RGDO" scenario. I get the feeling we are seeing some serious positioning in advance of this. Very interesting times.